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A B S T R A C T
Genome wide association studies have implicated intestinal barrier function genes in the pathogenesis
of ulcerative colitis. One of such loci CDH1, encoding E-cadherin, a transmembrane glycoprotein with
known tumor suppressor functions, is also linked to the susceptibility to colorectal cancer. Loss of
membranous E-cadherin expression is common in both colitis and cancer. We have recently
demonstrated that mesalamine (5-ASA); the anti-inﬂammatory drug used to treat ulcerative colitis,
induces membranous expression of E-cadherin and increases intercellular adhesion. Using colorectal
cancer epithelial cells with aberrant E-cadherin expression, we investigated the mechanism underlying
such an effect of 5-ASA. Post-translational modiﬁcation of E-cadherin glycosylation was analyzed by
biotin/streptavidin detection of sialylated glycoproteins. GnT-III (N-acetylglucosaminyltransferase III)
expression was assessed by qRT-PCR, Western blot and immunoﬂuorescence. GnT-III activity was
analyzed by reactivity with E-4/L-4-PHA. Expression, localization and interaction of E-cadherin and b-
catenin were analyzed by Western blot, immunocytochemistry and RNA interference. 5-ASA activity
modulated E-cadherin glycosylation and increased both mRNA and protein levels of GnT-III and its
activity as detected by increased E4-lectin reactivity. Intestinal APCMin polyps in mice showed low
expression of GnT-III and 5-ASA was effective in increasing its expression. The data demonstrated that
remodeling of glycans by GnT-III mediated bisect glycosylation, contributes to the membranous
retention of E-cadherin by 5-ASA; facilitating intercellular adhesion. Induction of membranous
expression of E-cadherin by 5-ASA is a novel mechanism for mucosal healing in colitis that might impede
tumor progression by modulation of GnT-III expression.
 2013 The Authors. Published by Elsevier Inc. 
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Ulcerative colitis (UC) is a form of inﬂammatory bowel disease
(IBD) causing chronic inﬂammation of the colon. 5-ASA, the primary
anti-inﬂammatory therapy in UC, induces mucosal healing in the
majority of patients, although the underlying molecular mechanism
is incompletely understood [1]. Chronic gut inﬂammation in UC
disrupts the intestinal architecture as a consequence of altered       
Abbreviations: CRC, colorectal cancer; IBD, inﬂammatory bowel diseases; UC,
ulcerative colitis; GnT-III, N-acetylglucosaminyltransferase-III; AJ, adherens junc-
tion; PAK1, p21 activated kinase 1.
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Open access under CC BY-NC-SA licefunction of molecules involved in epithelial integrity. Several
transmembrane proteins are involved in the establishment and
maintenance of the intercellular adhesion. Adherens junctions (AJs)
are composed of multiprotein complexes, which are uniformly
distributed along the plasma membrane and provide adhesive
contact for intercellular adhesion. Establishment of polarized
epithelia requires cell to cell contact that induces formation of AJs
followed by assembly of tight junctions [2]. E-cadherin, a member of
the cadherin family of transmembrane molecules, plays a dynamic
role in maintaining the homeostasis of intestinal epithelium.
Membranous expression of E-cadherin triggers assembly of AJs
through its adhesive interaction with armadillo family members and
cytoskeletal adapter proteins [3]. Abnormalities in epithelial
architecture through disruption of AJs and impaired expression of
E-cadherin are implicated in chronic gut inﬂammation and
colorectal cancer (CRC). Recently, a genome-wide association study
of UC identiﬁed CDH1 locus (encoding E-cadherin) which was also
identiﬁed as one of the susceptibility loci for CRC [4,5]. These
observations provide a link for the role of E-cadherin in both UC andnse.
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healing, and epithelial-mesenchymal transition of cancer cells [6,7].
Muise et al. demonstrated that IBD patients with the disease-
associated single nucleotide polymorphisms in CDH1, have in-
creased cytoplasmic accumulation of E-cadherin, likely as a result of
a processing defect [8]. We recently reported that 5-ASA results in
the membranous translocation of E-cadherin and concomitantly
increases intercellular adhesion [9] indicating a molecular basis of
its action in the restoration of epithelial barrier function in IBD
patients.
Several studies suggest that molecular organization, stability
and adhesive functions of E-cadherin can be modulated by
remodeling of glycan structure [10]. It has been demonstrated
previously that asparagine residues that undergo N-glycosylation
are located in the ectodomain of the E-cadherin molecule [11].
These potential glycosylation sites have been implicated in the
modulation of its function in pathophysiological conditions.
Within the N-glycan biosynthetic pathway, GnT-III (N-acetylglu-
cosaminyltransferase-III) introduces bisecting GlcNAc (N-acetyl-
glucosamine) and suppresses processing of branched or complex
glycans catalyzed by GnT-V. Bisecting glycans on E-cadherin delay
its turnover on the membrane and increases cell adhesion [12,13].
Using an epithelial cell line, Vagin et al. demonstrated that
silencing GnT-III facilitates branching and complexity of N-glycans
that was associated with increased permeability of the cell
monolayer [14]. Moreover, the structure of N-glycans modulated
by GnT-III on Na/K-ATPase, the cell adhesion protein investigated
in this study, was associated with establishment of tight
epithelium. GnT-III inhibited cytoplasmic and nuclear transloca-
tion of b-catenin from the membrane and transforming growth
factor-b1 (TGF-b1) downregulated E-cadherin and GnT-III during
epithelial-mesenchymal transition [15]. This confers a tumor
suppressor role on GnT-III, as overexpression of this enzyme is
associated with the inhibition of epithelial-mesenchymal transi-
tion and metastasis [16]. Altogether, these studies suggest that
activity of glycosyltransferases is critical in pathophysiology of the
disease and highlight them as attractive therapeutic targets.
Nevertheless, the effect of N-glycosylation in gut epithelium is not
well characterized. Considering the signiﬁcance of membranous E-
cadherin expression, which is critical for its role in epithelial
integrity and cancer progression, we examined the underlying
mechanism of membranous turnover of E-cadherin by 5-ASA and
its effect on E-cadherin glycosylation, using colorectal cancer cell
lines.
2. Materials and methods
2.1. Cell lines and reagents
Human colorectal carcinoma cell lines HCT116 and HT29
(obtained from ATCC) were grown in IMDM (Gibco/Invitrogen,
Lofer, Austria) containing 10% fetal bovine serum (FBS; Biochrom,
Berlin, Germany). 5-ASA (>99.9% pure; a generous gift from Shire
Inc., Eysins, Switzerland) was dissolved in the culture medium at
20 mM or 40 mM ﬁnal concentration (pH adjusted to 7.2 with
NaOH).
2.2. Immunoprecipitation and labeling of sialylated glycoproteins on
E-cadherin
HCT116 or HT29 cells were treated with 20 mM or 40 mM 5-
ASA (for 24 h or left untreated. For immunoprecipitation, cell
lysates were incubated with E cadherin antibody or control IgG,
followed by protein G plus agarose beads (Santa Cruz). The beads
were washed and either boiled directly in SDS sample buffer (for IP
Western blot) or subsequently processed for glycoprotein labeling.Biotin labeling of sialylated glycoproteins was carried out as
described [17], with minor modiﬁcations. Brieﬂy, IP-beads were
subjected to mild periodate oxidation with 1 mM NaIO4 at 4 8C,
20 min to generate a free aldehyde on sialic acids. Beads were
washed with PBS followed by an aniline-catalyzed oxime ligation
(PAL) with 100 mM aminooxy-biotin and 10 mM aniline in PBS (pH
6.7) for 90 min at 4 8C, to introduce a biotin tag. After washing with
PBS, beads were boiled in SDS gel sample buffer and proteins were
separated by SDS-PAGE. E-cadherin immunoblots were visualized
by the Odyssey Infrared Imaging System (LI-COR Biosciences).
Biotin labeling for sialylated glycoproteins was detected by a
Streptavidin Alexa Fluor 488 conjugate on a Typhoon 9200 image
scanner (Amersham Biosciences) or with IRDye 800CW Strepta-
vidin (LiCor). Endoglycosidase H treatment of E_cadherin (IP) was
performed according to manufacturer’s protocol (New England
Biolabs). One unit of Endo-H was used (1 h, 37 ?C).
2.3. Cell adhesion assay
Cell adhesion assay was performed as described previously [9].
pCMV5Bmyc plasmid, with wt E-cadherin or E-cadherin N-
glycosylation variant V13 (lacking site 1 in EC4 and site 3 in
EC5) was a kind gift from Maria A. Kukuruzinska (Boston
University, MA). CHO cells were transfected with the pCMV5Bmyc
vector using Effectene (Qiagen). Cells were treated with 5-ASA
(20 mM) for 24 h, washed in PBS, counted and an equal number of
cells were plated in 24-well plates allowing them to attach to the
surface. After 30 min of incubation, each plate was washed with
PBS until no ﬂoating cells remained and then replaced with the
fresh medium and MTT reagent. After 4 h, the medium was
removed and the remaining precipitates were dissolved in DMSO/
ethanol mixture (50/50 v/v) and absorbance was measured at
570 nm with an ELISA plate reader. The experiment was repeated
two times, and for each dish, four wells were scored.
2.4. RNA interference
Transfections were performed using Mammalian Epithelial
Cells Amaxa Basic Nucleofector Kit (Lonza, Basel, Switzerland) and
cells were electroporated according to manufacturer’s instruc-
tions. CTNNB1 FlexiTube siRNA was purchased from Qiagen
(Cambridge, MA) and prepared based on the manufactures
protocol. Control siRNA-A: sc-37007 (Santa Cruz Biotechnology,
CA) was also prepared based on the manufacturer’s instructions.
30 nM control siRNA and 30 nM CTNNB1 siRNA were utilized in all
transfection experiments.
2.5. Immunoﬂuorescence microscopy
Cells were ﬁxed in methanol and immunostaining was
performed using antibodies against b-catenin (clone 15B8;
eBioscience), E-cadherin (Clone 36; BD Transduction Laboratories),
GnT-III (F-20, Santa Cruz Biotechnology) PHA-L4-FITC and PHA-E4-
FITC (amsbio). For protein visualization AlexaFluor 488 and 568
antibodies (Invitrogen) were used. Nuclear staining was performed
using Vectashield with DAPI (Vector laboratories) for mounting.
Images were scanned at 400 magniﬁcation on a LSM 700 (Zeiss)
or Olympus BX 51). Digital images were processed with Zeiss LSM
Browser.
2.6. Cell fractionation, Western blotting and antibodies
For cytosolic and membrane fractions cells were grown in
15 cm dishes and were collected with 400 ml cold hypotonic buffer
(10 mM Tris–HCl pH 7.5, 0.2 mM MgCl2, with protease and
phosphatase inhibitors) with a cell scraper. The extract was
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spun at 15,000g for 45 min at 4 8C, and the supernatant was
collected as the cytosolic fraction. The pellet was washed twice in
hypotonic buffer and then resuspended by vortexing in 50 ml lysis
buffer (150 mM NaCl, 20 mM Tris–HCl pH 7.5, 1% Triton X-100, and
proteinase inhibitors). The extract was vortexed for 10 s every
10 min and kept on ice for 30 min. Afterwards, the supernatant was
collected as the membrane fraction. Both fractions were incubated
with Laemmli sample buffer containing 10% b-mercaptoethanol at
95 8C for 10 min and then analyzed by Western blot. Protein
concentrations were measured by Bradford assay (Bio-Rad).
Proteins were separated by SDS-PAGE and immunoblotted onto
a PVDF membrane. Primary antibodies used were as follows:
monoclonal antibody, anti-E-cadherin (clone 36 BD Transduction
Laboratories), anti-b-catenin (clone 14/BD Transduction Labora-
tories), alpha-tubulin (cell signaling), GnT-III (Santa Cruz). The
protein bands were visualized with anti-rabbit or anti-mouse
antibodies coupled to horseradish peroxidase using the ECL kit
(Amersham) or with IRDye coupled antibodies (either or both
mouse/rabbit) and scanned on Odyssey imager (LI-COR Biotech-
nology).
2.7. GnT-III mRNA expression
Cells were treated with 20 mM 5-ASA for 24 h. Total RNA was
extracted with TRIzol (Invitrogen). 1 mg of RNA was reverse
transcribed using the High Capacity cDNA Reverse Transcription
Kit (Applied Biosystems). qRT-PCR was performed using the Fast
SYBR Green Master Mix (Applied Biosystems) and run on the 7500
Fast Real-Time PCR System (Applied Biosystems). GnT-III (MGAT3)
QuantiTect Primer Assay (QT01004381) was obtained from Qiagen.
The reference housekeeping gene used was 36B4 that was found
not to be affected by 5-ASA treatment.
2.8. Animals and experimental procedure
The animal experiment was performed as reported earlier [9].
Brieﬂy, 4–6 week old heterozygous female and male C57BL/6J-
ApcMin/+ mice (Jackson Laboratories) were fed with either
2500 mg/kg 5-ASA (A3537, Sigma-Aldrich) mixed into the chow
or with a control diet (C1000, Altromin). The 5-ASA dose
corresponds to the intake of 3 g/day in humans [18]. After 12
weeks the mice were euthanized, the whole gut dissected and
coiled up to a Swiss roll. The intestine was ﬁxed in neutral buffered
formalin (10%) for 24 h and embedded in parafﬁn.
2.9. Immunohistochemistry
Immunohistochemistry analysis was done on parafﬁn-embed-
ded mouse intestine. Serial tissue sections (4 mm) Swiss rolls were
stained for GnT-III (F-20; sc-27287 Santa Cruz) using standard
procedures. Brieﬂy, slides were dried, de-waxed in xylol and
rehydrated using a decreasing alcohol series. After blocking of
endogenous peroxidase with 15% H2O2 in methanol, antigen
retrieval was performed in 10 mM citrate buffer, pH 6. Subse-
quently slides were blocked in 2% horse serum, 3% BSA in TRIS
buffer. GnT-III antibody was incubated 4 8C (overnight), followed
by biotinylated anti-goat antibody and avidin-biotin-HRP com-
plex. Staining was visualized using DAB and nuclear counter-
staining was performed using hematoxylin. Slides were
dehydrated and embedded in Histoﬂuid.
2.10. Statistical analysis
The data was analyzed by Student’s t-test. P-values less than
0.05 were considered statistically signiﬁcant.3. Results
3.1. 5-ASA mediated membranous turnover of E-cadherin is
independent of b-catenin
An interaction between E-cadherin and b-catenin is one of the
mechanisms of E-cadherin exocytosis on the cell membrane at AJs
[19]. To test whether 5-ASA utilizes this mechanism, we examined
the effect of silencing b-catenin on membranous expression of E-
cadherin. HT29 cells (which are mutated in APC, have activated b-
catenin signaling, and express low membranous E-cadherin) were
transfected with control (con-siRNA) or siRNA for b-catenin (sib-
catenin) in the presence or absence of 5-ASA. In con-siRNA cells, 5-
ASA treatment enhanced both E-cadherin and b-catenin localiza-
tion at AJs (Fig. 1a). Moreover, there was an increased membranous
co-localization of E-cadherin and b-catenin in con-siRNA cells
(merged picture), conﬁrming enhanced interaction of these
molecules upon 5-ASA treatment. Interestingly, in sib-catenin
transfected cells, 5-ASA still induced membranous expression of E-
cadherin. This observation indicated that the 5-ASA mediated
membranous turnover of E-cadherin was independent of its
interaction with b-catenin. Western blot was performed to
conﬁrm the ﬁndings of immunocytochemistry (Fig. 1b). Inhibition
of b-catenin did not alter the 5-ASA-induced membranous
increase in E-cadherin. Interestingly, the transmembrane protein
Na/K. ATPase that was used to verify the purity of the membrane
fraction also changed with E-cadherin expression. However, this
effect might be expected with an increase in membranous E-
cadherin as Na/K. ATPase is an essential component of the
junctional complex and contributes to adhesion function of E-
cadherin and epithelial polarity [14,20]. We concluded that 5-ASA
interferes with an alternative pathway involved in E-cadherin
trafﬁcking, which is independent of b-catenin.
3.2. 5-ASA modulates E-cadherin glycosylation
Post-translational modiﬁcation of E-cadherin by phosphoryla-
tion and glycosylation is implicated in the surface localization and
binding with catenins and other partners at AJs [13]. We
hypothesized that 5-ASA affects the structural modiﬁcation of E-
cadherin by remodeling of glycans. To test this, we examined E-
cadherin glycosylation in 5-ASA treated cells. Biotin labeling of
sialylated E-cadherin immunoprecipitates, followed by streptavi-
din detection revealed enhanced glycosylation of E-cadherin upon
5-ASA treatment (Fig. 2a). Both of the cell lines examined showed
an increase in E-cadherin glycosylation as observed by high
molecular weight bands. Enzymatic de-glycosylation by Endo-H
resulted in the removal of glycosylated E-cadherin (Fig. 2b and c).
The appearance of the E-cadherin glycosylated band and its
disappearance upon Endo-H treatment indicates that 5-ASA
induced modiﬁcation of E-cadherin N-glycosylation could not be
complex N-glycans, as these are resistant to Endo-H.
It is known that E-cadherin can be modiﬁed by O-glycosylation
and N-glycosylation. The former prevents its transport to the cell
membrane [21], and N-glycosylation is the prominent modiﬁca-
tion which varies in its composition. Moreover, N-glycans at E-
cadherin ectodomain were found to affect E-cadherin mediated
cell adhesion [13]. To verify the role of N-glycosylation in 5-ASA
mediated cell adhesion, we utilized an E-cadherin N-glycosylation
mutant V13. It was demonstrated that CHO cells (that do not
express endogenous E-cadherin), can organize E-cadherin-medi-
ated AJs when transfected with E-cadherin [10]. CHO cells were
transfected with E-cadherin wild-type or the V13 N-glycosylation
mutant. Wild-type (wt) E-cadherin transfectants displayed in-
creased adherence upon 5-ASA treatment (Fig. 2d), whereas no
such effect was observed in V13-mutant transfected CHO cells.
Fig. 1. Effect of silencing b-catenin on mesalamine (5-ASA) induced membranous translocation of E-cadherin. (a) HT29 cells were transfected with control and sib-catenin
RNA. Cells were grown on coverslips and treated with 5-ASA (20 mM) for 24 h. Immunostaining was performed using antibodies against b-catenin and E-cadherin. 5-ASA
induced membranous translocation of both proteins. An increased interaction of b-catenin and E-cadherin was observed upon 5-ASA treatment in cells transfected with
control RNA (merged image). Membranous turnover of E-cadherin was unaffected upon 5-ASA treatment in sib-catenin transfected cells. Image magniﬁcation 400 (b)
Western blot analysis of E-cadherin and b-catenin in total cell lysate (RIPA) and cellular fractions (membrane or cytoplasm) in sib-catenin transfected cells. Anti-tubulin was
used as loading control and Na–K ATPase was used to verify the purity of membranous fraction.
V. Khare et al. / Biochemical Pharmacology 87 (2014) 312–320 315These observations demonstrated that 5-ASA modulates E-
cadherin N-glycosylation, which affects cell adhesion. Using ECIS
(electric cell-substrate impedance sensing), we have previously
demonstrated that 5-ASA treatment affects intercellular adhesion.
Moreover, 5-ASA activity resulted in membranous recruitment of
AJ proteins [9]. Hence, we concluded that the increase in
intercellular adhesion upon 5-ASA treatment is associated with
remodeling of E-cadherin N-glycosylation.
3.3. GnT-III expression is upregulated by 5-ASA
It was clear that 5-ASA activity restored membranous expres-
sion of E-cadherin but it was independent of b-catenin. However,
N-glycosylation was critical for increased cell adhesion. We
speculated if modulation of N-glycosylation by 5-ASA contributes
to the membranous retention of E-cadherin resulting in the
stability of AJs.
Complexities of glycans that modify E-cadherin differ in
proliferating cells where adhesion is inhibited compared to cells
forming tight AJs restricting motility [10]. It has been shown that
GnT-III modiﬁes E-cadherin prolonging its membranous turnover
and overexpression of this enzyme is responsible for enhancedadhesion [7]. We reasoned that 5-ASA-mediated modulation of E-
cadherin glycosylation might promote AJ formation and hence,
increased intercellular adhesion. We examined the expression
levels of GnT-III upon 5-ASA treatment. Since addition of glycans
on E-cadherin can also take place in the junctional complex at the
cell membrane, we also examined the membrane fractions of these
cells. 5-ASA induced a marked increase in GnT-III protein in
HCT116 cells but only in the membranous fraction of HT29 cells
(Fig. 3a). When assessing the effect of 5-ASA on the relative
expression of GnT-III mRNA (MGAT3), an increase in MGAT3
transcripts was observed in both cell lines examined, the effect
being more pronounced in HCT116 (Fig. 3b). Overall, the two cell
lines examined differed in the expression of GnT-III. HT-29 cells
expressed membranous GnT-III suggesting its activity at AJs.
However, HCT116 showed a relatively higher increase in both
MGAT3 mRNA and total protein levels upon 5-ASA treatment. To
further validate these ﬁndings, immunoﬂuorescence for GnT-III
was performed in the presence or absence of 5-ASA. The cellular
localization of GnT-III was not limited to cytoplasm. Although, the
glycosyltransfereases are localized in Golgi complex, the protein
was also present at the membrane in the CRC cells examined.
Consistent with Western blot data, 5-ASA treatment resulted in an
Fig. 2. 5-ASA modulates E-cadherin glycosylation. (a) Flow chart for the glycosylation assay performed on immunoprecipitated E-cadherin from HCT116 and HT29. (b) As
indicated, Western blot was performed either on E-cadherin IP (5-ASA) or on E-cadherin IP subjected to biotinylation (5-ASA). Treatment increased glycosylation of E-cadherin
(lane 60) compared to untreated controls (lane 40) which was detected as multiple high molecular weight bands. The experiment was performed again in the presence or absence of
glycosidase Endo-H (right panel). Treatment with Endo-H resulted in the removal of 5-ASA induced glycosylated band (*) and a shift in E-cadherin band (*). (c) E-cadherin
glycosylation assay with HT29 cells. *Indicate appearance of glycosylated band upon 5-ASA treatment (lane 20) or shift in E-cadherin band upon glycosidase treatment. (d) Cell
adhesion assay performed with CHO cells transfected with either wild type E-cadherin or N-glycosylation variant V-13 constructs. 5-ASA (20 mM; 24 h) increased cell adhesion in
the cells with wt-E-cadherin but not in the cells transfected with E-cadherin V13 mutant. All N-glycosylation sites are intact in the wt-E-cadherin ectodomains (EC 4 and 5) while
V13 mutant lacks Asn-404 and Asn-483.
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Fig. 3. 5-ASA increases GnT-III expression. (a) Western blot with anti-GnT-III antibody upon 5-ASA (5-ASA; 20 mM) treatment of the cells in the whole cell extract (RIPA) or
membranous fractions. a-tubulin was used as loading control (b) validation of increased transcription of GnT-III by qRT-PCR in 5-ASA treated (20 mM;24 h) cell lines. *p
value = 0.018 (c) immunoﬂuorescent detection for GnT-III expression in HCT116 and HT29 cells. Arrows indicate cell contacts. Image magniﬁcation 400.
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modulated its localization at cell-to cell contacts (Fig. 3c).
Altogether, this data supported the notion that 5-ASA modulates
GnT-III expression in CRC cells.
3.4. 5-ASA treatment inhibits L-PHA reactivity and increases bisecting
glycans identiﬁed by E-PHA
5-ASA treatment modiﬁed N-glycosylation of E-cadherin with
an increase in GnT-III expression in CRC cells. To further evaluate
the products of GnT-III (bisecting GlcNAc) we performed lectin
staining that distinguishes the products of GnT-III and GnT-V. TheFig. 4. Detection of bisecting or branched GlcNAc structures. E-PHA and L-PHA lectin react
(L4-PHA) were predominant suggesting higher activity of GnT-V. 5-ASA treatment inh
structures was observed conﬁrming increase in GnT-III enzymatic activity. Image magbisecting glycans are preferentially recognized by E4-PHA while
L4-PHA recognizes branched GlcNAc (product of GnT-V). In
untreated cells, L4-PHA reactivity was higher compared to E4-
PHA indicating higher GnT-V activity. 5-ASA treatment resulted in
marked inhibition of L4-PHA reactivity and increased glycans
recognized by E4-PHA (Fig. 4) conﬁrming the increase in GnT-III
activity. This effect was more pronounced in HCT116 cells
consistent with modulation of GnT-III expression by 5-ASA.
The inhibition of L4-PHA reactivity upon 5-ASA treatment
indicated inhibition of GnT-V activity. While E4-PHA reactivity
demonstrated increased activity of GnT-III in 5-ASA treated cells.
These results were in accordance with our previous observationivity was assessed by immunoﬂuorescence. In untreated CRC cells, branched GlcNAc
ibited GnT-V activity and an increased expression of bisecting GlcNAc (E4-PHA)
niﬁcation 400.
Fig. 5. 5-ASA modulates GnT-III expression in vivo. Immunohistochemistry was performed on tissue sections from APCMin mice. Small intestinal APCMin polyp showed low
expression of GnT-III while surrounding normal mucosa stained GnT-III positive with moderate expression (indicated by arrow). 5-ASA activity increased expression of GnT-
III in mucosal lining. Image magniﬁcation 40. Higher magniﬁcation (100) shows that more cells stained GnT-III positive in the polyp from mice with 5-ASA in their diet as
indicated by arrows. The ﬁgure represents polyps from the ileum.
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HCT116 compared to HT29 [9]. We concluded that increased
expression of GnT-III by 5-ASA modiﬁes glycan structures on E-
cadherin, facilitates its membranous retention and promotes
intercellular adhesion.
3.5. 5-ASA induced GnT-III expression in vivo
We further utilized tissue sections from our experiments in the
APCMin mouse model of intestinal tumorigenesis, to examine the
effect of 5-ASA activity on GnT-III expression in vivo [9]. APCMin
mice develop spontaneous intestinal polyps due to mutation in the
APC gene [22]. Our data and others have shown that 5-ASA reduced
the number of polyps in these mice and restored membranous E-
cadherin which showed aberrant expression in untreated polyps
[9,23,24]. Immunohistochemistry was performed on intestinal
sections from the mice kept on a 5-ASA diet as well as the
untreated control group. GnT-III was moderately expressed in the
cytoplasm of normal mucosa and APCMin polyps showed low
expression of GnT-III (Fig. 5). 5-ASA treatment increased Gnt-III
expression, both in the polyps and in the normal mucosa. The
surrounding tissue also stained positive for GnT-III suggesting its
role in the modiﬁcation of mucus glycoproteins and/or staining for
secreted protein. This data provided evidence that GnT-III
expression and therefore, complexity of glycans, is modulated
by 5-ASA activity.4. Discussion
We have previously shown that 5-ASA activity is involved in E-
cadherin/b-catenin-mediated intercellular adhesion through in-
duction of membranous E-cadherin. While examining the mecha-
nism of membranous E-cadherin expression by 5-ASA, the current
study demonstrated that the 5-ASA modulates E-cadherin N-
glycosylation. The increase in cell adhesion is dependent on N-
glycosylation of E-cadherin as cells expressing the V13 N-
glycosylation mutant, did not show this effect upon 5-ASA
treatment. The data showed that N-glycosylation is modulated
by 5-ASA through re-modeling of glycan structures that contribute
to membranous retention of E-cadherin. 5-ASA-induced membra-
nous translocation of E-cadherin was independent of b-catenin.
Albeit, 5-ASA activity was found to be associated with upregulation
of glycosyltransferase GnT-III, that stabilizes membranous E-
cadherin. The increase in GnT-III activity was associated with
decreased L4-PHA reactivity; indicating suppression of GnT-V
activity and a concomitant increase in the bisect glycans
recognizing E4-PHA. The increase in GnT-III expression by 5-ASA
was also observed in APCMin polyps. This study provides a
mechanistic explanation that GnT-III mediated modulation of
bisect N-glycosylation on E-cadherin might be fostering its
membranous retention, thereby promoting intercellular cell
adhesion by 5-ASA. Remodeling of N-glycans by 5-ASA is a novel
mechanism of its action in intestinal homeostasis.
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is attributed to transcriptional repression, promoter methylation
along with altered post-translational modiﬁcations including
glycosylation [7,25]. Little is known regarding the role of N-
glycans, the most prominent modiﬁcation on E-cadherin, in the
assembly and stability of AJs. Quantitative and qualitative changes
in E-cadherin N-glycosylation were found to affect the molecular
organization of AJs [10]. Bisecting glycans were shown to increase
E-cadherin-mediated cell adhesion and reduce integrin-mediated
cell spreading and migration [13]. These studies emphasize the
signiﬁcance of N-glycosylation and N-acetylglucosaminyltrans-
ferases in the impairment of E-cadherin functions in diseases such
as IBD and cancer. We did not utilize an approach to silence GnT-III
and validate the effect of 5-ASA on membranous translocation of E-
cadherin. However, another study demonstrated that depletion of
GnT-III resulted in membranous de-localization of E-cadherin
without affecting its mRNA or protein levels [26]. The E-cadherin-
catenin complex itself regulates GnT-III enzymatic activity [27]
and our data supports this notion. The membranous increase of
GnT-III upon 5-ASA treatment suggests its enzymatic activity in E-
cadherin junctional complex and the likely cause of membranous
retention of E-cadherin.
In a study from Jamal et al. [28], a hypo-glycosylated E-cadherin
V13 mutant promoted the formation of stable AJs compared to
wild-type. Using the same E-cadherin variant, however, we
observed that 5-ASA was ineffective in increasing cell adhesion
when the cells were transfected with the V13 mutant. Current data
primarily suggest a role of GnT-III upregulation and glycan
remodeling by 5-ASA; therefore, the possibility that the V13
residue is critical in GnT-III-induced alteration in glycan structure
cannot be ruled out.
Upregulation of GnT-III expression and bisect glycosylation by
5-ASA might be attributed to inhibition of Wnt/b-catenin
signaling. 5-ASA inhibits b-catenin nuclear localization and
transcriptional activity. We have recently shown that 5-ASA
activity is mediated by inhibition of serine–threonine kinase PAK1
and inhibition of PAK1 increased membranous localization of E-
cadherin and b-catenin. PAK1 phosphorylates b-catenin and
contributes to Wnt/b-catenin signaling. On other hand, activation
of the Wnt/b-catenin pathway inhibited GnT-III expression [29].
Nevertheless, 5-ASA is an anti-inﬂammatory drug and modulates
several pathways besides Wnt/b-catenin signaling. TGF-beta
signaling induces GnT-V and inhibits Gnt-III; while 5-ASA acts
as an antagonist for TGF-beta signaling [30]. Taken together, our
data demonstrates that pharmacological inhibition of PAK1 and
upregulation of Gnt-III by 5-ASA can reverse the impairment of E-
cadherin membranous expression in CRC cells.
Our in vivo data in an APCMin mouse model gives a novel insight
about GnT-III expression in intestinal polyposis. Though 5-ASA is
not effective in lowering tumor incidence in this model, it does
have an impact in lowering tumor multiplicity [23]. Upregulation
of a metastasis suppressor protein like GnT-III, supports the
beneﬁcial effects of 5-ASA in restricting tumor burden. Knowledge
about protein glycosylation in the development of intestinal
disease is lacking. Further investigations are needed to understand
the role of glycosyltransferses in the maintenance of gut
physiology.
E-cadherin is critical in the establishment and maintenance of
cell adhesion; it regulates intercellular contacts via several
mechanisms. Reduced cell adhesiveness is associated with an
increase in mucosal permeability. This study provides a mecha-
nistic link for 5-ASA activity in improving intestinal barrier
function through modulation of N-glycosylation. We propose that
5-ASA activity contributes in the interplay of an increased GnT-III
expression and turnover of E-cadherin in the complex with b-
catenin at AJs, thereby promoting intercellular adhesion. It is likelythat 5-ASA might be interfering with E-cadherin endocytosis in
CRC cells examined. Modulation of N-glycosylation associated with
an upregulation of GnT-III is a novel mechanism of 5-ASA’s activity,
which can have implications in restoration of epithelial integrity in
UC and in impeding tumor progression in colorectal carcinogene-
sis. 5-ASA might be effective in maintaining epithelial barrier
function in other conditions leading to enhanced intestinal
permeability such as NSAID colitis, graft-versus-host disease,
multiple trauma and sepsis.
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